CoChat
Sign Up
Cited by 6

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors

Yasugi, Masayuki, Takigawa, Nagio, Ochi, Nobuaki, Ohashi, Kadoaki, Harada, Daijiro, Ninomiya, Takashi, Murakami, Toshi, Honda, Yoshihiro, Ichihara, Eiki, Tanimoto, Mitsune, Kiura, Katsuyuki·2014·Experimental Cell Research
DOI 10.1016/j.yexcr.2014.04.012
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.yexcr.2014.04.012

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 40

  1. Sasaki, 2010, The biology and treatment of EML4-ALK non-small cell lung cancer, Eur. J. Cancer, 46, 1773, 10.1016/j.ejca.2010.04.002 · DOI
  2. Sun, 2010, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases, J. Clin. Oncol., 28, 4616, 10.1200/JCO.2010.29.6038 · DOI
  3. Kim, 2011, Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement, Cancer
  4. Kim, 2011, The BATTLE trial: personalizing therapy for lung cancer, Cancer Discovery, 1, 44, 10.1158/2159-8274.CD-10-0010 · DOI
  5. Li, 2013, Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies, J. Clin. Oncol., 31, 1039, 10.1200/JCO.2012.45.3753 · DOI
  6. Mitsudomi, 2007, Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer, Cancer Sci., 98, 1817, 10.1111/j.1349-7006.2007.00607.x · DOI · Paper page
  7. Mok, 2009, Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med., 361, 947, 10.1056/NEJMoa0810699 · DOI · Paper page
  8. Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, N. Engl. J. Med., 361, 958, 10.1056/NEJMoa0904554 · DOI · Paper page
  9. Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med., 362, 2380, 10.1056/NEJMoa0909530 · DOI · Paper page
  10. Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol., 12, 735, 10.1016/S1470-2045(11)70184-X · DOI · Paper page
  11. Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 13, 239, 10.1016/S1470-2045(11)70393-X · DOI · Paper page
  12. Gazdar, 2010, Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy, Cancer Metastasis Rev., 29, 37, 10.1007/s10555-010-9201-z · DOI
  13. Giaccone, 2011, Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors, Cancer Treat. Rev., 37, 456
  14. Gately, 2012, Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study, Lung Cancer, 75, 217, 10.1016/j.lungcan.2011.06.012 · DOI
  15. Gridelli, 2008, The potential role of mTOR inhibitors in non-small cell lung cancer, Oncologist, 13, 139, 10.1634/theoncologist.2007-0171 · DOI
  16. Boulay, 2004, Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells, Cancer Res., 64, 252, 10.1158/0008-5472.CAN-3554-2 · DOI
  17. Ogino, 2007, Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line, Cancer Res., 67, 7807, 10.1158/0008-5472.CAN-07-0681 · DOI
  18. Ohashi, 2009, Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice, Cancer Res., 69, 7088, 10.1158/0008-5472.CAN-08-4205 · DOI
  19. Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 · DOI · Paper page
  20. Kawada, 2002, Comparison of chemosensitivity tests: clonogenic assay versus MTT assay, Acta Med. Okayama, 56, 129
  21. Rodrik-Outmezguine, 2011, mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling, Cancer Discovery, 1, 248, 10.1158/2159-8290.CD-11-0085 · DOI · Paper page
  22. Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 · DOI · Paper page
  23. Sun, 2005, Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition, Cancer Res., 65, 7052, 10.1158/0008-5472.CAN-05-0917 · DOI
  24. Hotchkiss, 2009, Cell death, N. Engl. J. Med., 361, 1570, 10.1056/NEJMra0901217 · DOI
  25. Vu, 2010, Target of rapamycin signaling in leukemia and lymphoma, Clin. Cancer Res., 16, 5374, 10.1158/1078-0432.CCR-10-0480 · DOI
  26. Li, 2011, Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1, Cancer Res., 71, 3625, 10.1158/0008-5472.CAN-10-4475 · DOI · Paper page
  27. Castedo, 2002, Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic, Cell Death Differ., 9, 99, 10.1038/sj.cdd.4400978 · DOI
  28. Anagnostou, 2009, High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma, Clin. Cancer Res., 15, 4157, 10.1158/1078-0432.CCR-09-0099 · DOI
  29. Yoshizawa, 2010, Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer, Clin. Cancer Res., 16, 240, 10.1158/1078-0432.CCR-09-0986 · DOI
  30. Dhillon, 2010, Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer, J. Thorac. Oncol., 5, 314, 10.1097/JTO.0b013e3181ce6604 · DOI
  31. Liu, 2011, Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma, Cancer, 117, 3763, 10.1002/cncr.25959 · DOI
  32. Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat. Med., 8, 128, 10.1038/nm0202-128 · DOI
  33. Han, 2011, EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells, PLoS One, 6, e18691, 10.1371/journal.pone.0018691 · DOI
  34. Li, 2013, Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer, Lung Cancer, 10.1016/j.lungcan.2013.05.012 · DOI
  35. Choi, 2013, Autophagy in human health and disease, N. Engl. J. Med., 368, 651, 10.1056/NEJMra1205406 · DOI · Paper page
  36. Ishikawa, 2013, mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF, PLoS One, 8, e62104, 10.1371/journal.pone.0062104 · DOI
  37. Buck, 2006, Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors, Mol. Cancer Ther., 5, 2676, 10.1158/1535-7163.MCT-06-0166 · DOI
  38. La Monica, 2009, Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines, Biochem. Pharmacol., 78, 460, 10.1016/j.bcp.2009.04.033 · DOI
  39. Dong, 2012, Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors, Cancer Chemother. Pharmacol., 70, 707, 10.1007/s00280-012-1946-3 · DOI
  40. Soria, 2009, Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors, Ann. Oncol., 20, 1674, 10.1093/annonc/mdp060 · DOI

Cited by

Sorted by citations

Metadata

Authors
Yasugi, M., Takigawa, N., Ochi, N., Ohashi, K., Harada, D., Ninomiya, T., Murakami, T., Honda, Y., Ichihara, E., Tanimoto, M., & Kiura, K.
Venue
Experimental Cell Research
Publisher
Elsevier BV
Published
2014-08
Volume
326
Issue
2
Pages
201-209
ISSN
0014-4827
DOI
10.1016/j.yexcr.2014.04.012
Cited by
6
References
3
Language
en
Licence
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (23390221, 23B-30, 24591182)
  • Kawasaki Medical School

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review